Stephanie Davis
Stock Analyst at Barclays
(0.76)
# 3,930
Out of 5,024 analysts
96
Total ratings
32.84%
Success rate
-108.37%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $185 → $190 | $187.35 | +1.41% | 6 | Oct 2, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $36.73 | +22.52% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $20.39 | -75.48% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $68.05 | +10.21% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.19 | +34.87% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.02 | +49.25% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $7.84 | +142.35% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $319.61 | -9.26% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $27.85 | -13.82% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $155.67 | -14.56% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $29.92 | +93.85% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.99 | +0.33% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $282.75 | -11.94% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $22.93 | +26.47% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $8.94 | +280.31% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $20.32 | +67.32% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $287.38 | -18.92% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.06 | +455.56% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $92.55 | -17.88% | 5 | Jun 7, 2022 |
Quest Diagnostics
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $185 → $190
Current: $187.35
Upside: +1.41%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $36.73
Upside: +22.52%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $20.39
Upside: -75.48%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $68.05
Upside: +10.21%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.19
Upside: +34.87%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.02
Upside: +49.25%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $7.84
Upside: +142.35%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $319.61
Upside: -9.26%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $27.85
Upside: -13.82%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $155.67
Upside: -14.56%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $29.92
Upside: +93.85%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.99
Upside: +0.33%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $282.75
Upside: -11.94%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $22.93
Upside: +26.47%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $8.94
Upside: +280.31%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $20.32
Upside: +67.32%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $287.38
Upside: -18.92%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.06
Upside: +455.56%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $92.55
Upside: -17.88%